- Boman H, Hedelin H, Holmäng S. Four bladder tumour markers (NMP22, BTA stat, VBC and cytology) have a disappointingly low sensitivity for small-sized and low grade recurrences. J Urol 2002; 167: 80-3.
- Reading J, Hall RR, Parmar MKB. The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice. Br J Urol 1995; 75: 604-7.
- Neymark N, Torfs K. Economics of urinary tract cancers: state of theoart. Eur Urol 1997; 31 (Suppl 1): 72-81.
- Fosså SD, Åass N, Ous S, Waehre H, liner K, Hanisdal E. Survival after curative treatment of muscle invasive bladder cancer. Acta Oncol 1996; 35 (Suppl 8): 59-65.
- Hedelin H, Holmäng S, Wiman E. Out-patient treatment of bladder cancer-lower cost and satisfied patients. Nord Med 1997; 112:48-51.
- Wright MPJ, Jones DJ. Surveillance for bladder cancer--the management of 4.8 million people. Br J Urol 2000; 85: 431-3.
Scandinavian Journal of Urology and Nephrology
Volume 36, 2002 - Issue 5